



RECEIVED  
NOV 15 2001  
TECHNOLOGY CENTER 2800

Abstract of the Disclosure

A disease associated with inflammation under non-ischemic conditions is treated or prevented by administering (1)  $\alpha$ -melanocyte simulating hormone ( $\alpha$ -MSH) and/or a  $\alpha$ -MSH equivalent, and/or (2) erythropoietin (EPO) and/or an EPO equivalent, to the individual in need thereof.

RECEIVED  
DEC 27 2001  
TECH CENTER 1600/2900